Abstracts tagged "matrix metalloproteinase (MMP) and rheumatoid arthritis"

Abstract Number: 1166 • 2015 ACR/ARHP Annual Meeting
Expression and Function of Proviral Integration Site for Moloney Murine Leukemia Virus 1 (PIM-1) Kinase in Rheumatoid Arthritis Fibroblast-like Synoviocytes
Yong Seok Choi¹, You Jung Ha², Jaehyung Hur³, Eun Ha Kang⁴, Yeong Wook Song⁵ and Yun Jong Lee², ¹Internal Medicine, Seoul National University Bundang Hospital, Seongnam-si, South Korea, ²Division of Rheumatology, Department of Internal Medicine,Seoul National University Bundang Hospital, Seongnam, South Korea, ³Division of Rheumatology, Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam-si, South Korea, ⁴Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam-si, South Korea, ⁵Division of Rheumatology, Department of Internal Medicine, Seoul National University Hospital, Seoul, South Korea
Background/Purpose: The Proviral Integration site of Moloney murine leukemia virus (PIM) kinases are important mediators of cell survival and considered as attractive targets in cancer…
Abstract Number: 2399 • 2013 ACR/ARHP Annual Meeting
Altered Histone Methylation Is Associated With IL-6 Dependent Matrix Metalloproteinases Gene Transcriptional Activation In Rheumatoid Arthritis Synovial Fibroblasts
Yasuto Araki^1,2, Takuma Tsuzuki Wada^1,2, Kojiro Sato¹, Kazuhiro Yokota¹, Fumihiko Miyoshi¹, Yu F. Asanuma³, Yuji Akiyama¹ and Toshihide Mimura^1,2, ¹Department of Rheumatology and Applied Immunology, Faculty of Medicine, Saitama Medical University, Saitama, Japan, ²Project Research Division, Research Center for Genomic Medicine, Saitama Medical University, Saitama, Japan, ³Department of Rheumatology and Applied Immunology, Saitama Medical University, Saitama, Japan
Background/Purpose: Rheumatoid arthritis (RA) is a chronic inflammatory autoimmune disease which causes progressive joint destruction. In spite of the modern medications including biologic reagents, it…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].